TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12499338

Group type: EXPERIMENTAL
Intervention: Basic meal with 50 g pork
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Basic meal with 75 g pork
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic meal with 25 g pork
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic meal (control)
Number of subjects: 45
Study: 11096386

Group type: EXPERIMENTAL
Intervention: Epidermal cooling with IPL treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-cooled IPL treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Crossover treatment with cooling
Number of subjects: 25
Study: 8558209

Group type: EXPERIMENTAL
Intervention: G‐CSF 5 micrograms/kg on days 1 to 12 and GM‐CSF at 0.5, 1, or 5 micrograms/kg on days 7 to 12
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GM‐CSF 5 micrograms/kg on days 1 to 12 and G‐CSF 5 micrograms/kg on days 7 to 12
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: G‐CSF added to patients already receiving GM‐CSF (cohort 4)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GM‐CSF added to patients already receiving G‐CSF
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Baseline apheresis CFU‐GM content
Number of subjects: 5
Study: 1911129

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 105
Study: 7065884

Group type: EXPERIMENTAL
Intervention: Vagotomy and pyloroplasty
Number of subjects: 344

Group type: COMPARATOR
Intervention: Vagotomy and hemigastrectomy
Number of subjects: 344
Study: 31996613

Group type: EXPERIMENTAL
Intervention: Caffeine (280 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee)
Number of subjects: 10
Study: 31030870

Group type: EXPERIMENTAL
Intervention: CBM-I (Cognitive Bias Modification for Interpretation)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: CBM-I
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (neutral WSAP task or treatment as usual)
Number of subjects: 127
Study: 28933711

Group type: EXPERIMENTAL
Intervention: Hip joint angle at 145° (hip145)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hip joint angle at 175° (hip175)
Number of subjects: 28
Study: 25673979

Group type: EXPERIMENTAL
Intervention: Mécano‐Stimulation™
Number of subjects: 30
Study: 24717956

Group type: EXPERIMENTAL
Intervention: Absorbable gelatin dressing impregnated with triamcinolone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 22866291

Group type: EXPERIMENTAL
Intervention: 5 × 5 mm dental implants with a novel nanostructured calcium‐incorporated titanium surface
Number of subjects: 80

Group type: COMPARATOR
Intervention: at least 5 × 10 mm‐long implants in augmented bone
Number of subjects: 80
Study: 19682360

Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine (DAM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral methadone (MMT)
Number of subjects: 62
Study: 17440010

Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15311110

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8206

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8206
Study: 15894527

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10618798

Group type: EXPERIMENTAL
Intervention: Quality assessment methods (thresholds, quality and variability relationship, sensitivity analysis, quality scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidated Standards of Reporting Trials (CONSORT) initiative
Number of subjects: 0
Study: 8740604

Group type: EXPERIMENTAL
Intervention: Randomized electrical tooth stimulation at 6 different levels of intensity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant intensity stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized stimulation with a 1-sec interstimulus interval (ISI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized stimulation with a prolonged ISI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized stimulation with a 3-sec ISI
Number of subjects: 0
Study: 1890501

Group type: EXPERIMENTAL
Intervention: High craving group (n=39)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Low craving group (n=115)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Moderate-to-high withdrawal symptom severity group (n=151)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Low withdrawal symptom severity group (n=27)
Number of subjects: 179
Study: 6804162

Group type: EXPERIMENTAL
Intervention: Mestranol 50 micrograms + Norethisterone 1mg (MES 50 + NET 1)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 micrograms + Levonorgestrel 150 micrograms (EE 30 + LNG 150)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Norethisterone 350 micrograms (NET 350)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 30 micrograms (LNG 30)
Number of subjects: 518
Study: 30951166

Group type: EXPERIMENTAL
Intervention: PrabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study: 31390743

Group type: EXPERIMENTAL
Intervention: Training in classroom behaviour management (mean 11.5 hours over 8 months)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 220
Study: 29630796

Group type: EXPERIMENTAL
Intervention: Sealing group (n=48, 27 AM; 21 RC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n=89, 59 AM; 30 RC)
Number of subjects: 34
Study: 27244762

Group type: EXPERIMENTAL
Intervention: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 1-2 of the cycle (Group A)
Number of subjects: 181

Group type: COMPARATOR
Intervention: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 20-22 of the previous cycle (Group B)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: GnRH‐a (Triptorelin) subcutaneous daily injections (both groups)
Number of subjects: 181
Study: 24928295

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study: 22343005

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulative intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 56
Study: 20052352

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 IU/day) in group S
Number of subjects: 3

Group type: COMPARATOR
Intervention: Breast-fed (group B) and breast-fed with vitamin D supplementation (group S)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Total intake of vitamin D in groups A, S, and B
Number of subjects: 3

Group type: COMPARATOR
Intervention: Total intake of Ca and P in groups A, B, and S
Number of subjects: 3
Study: 17610534

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg qd for 3 days, then 80 mg qd for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study: 16244051

Group type: EXPERIMENTAL
Intervention: Propensity score analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classification tree analysis and bagging for classification trees
Number of subjects: 0
Study: 12366619

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 295

Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 295
Study: 10448545

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylic acid (L-ASA) 1.8 g i.v. (1 g acetylsalicylic acid)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 7576743

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 139
Study: 30632837

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus chemotherapy (G + chemo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab plus chemotherapy (R + chemo)
Number of subjects: 0
Study: 30167783

Group type: EXPERIMENTAL
Intervention: ICBNB proximal approach (group P)
Number of subjects: 70

Group type: COMPARATOR
Intervention: ICBNB distal approach (group D)
Number of subjects: 70
Study: 27339661

Group type: EXPERIMENTAL
Intervention: Combined AUDADIS‐IV (n=166)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Explicit withdrawal stem (n=167)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Explicit hangover stem (n=164)
Number of subjects: 497
Study: 23334749

Group type: EXPERIMENTAL
Intervention: Live Well intervention (lifestyle intervention to prevent weight gain)
Number of subjects: 383
Study: 22707132

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVFX) 250 mg orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19166694

Group type: COMPARATOR
Intervention: Nicotinic acid (1,500 mg/day) plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1,500 mg/day) plus gemfibrozil (1,200 mg/day)
Number of subjects: 0
Study: 17151802

Group type: COMPARATOR
Intervention: Omeprazole (high-dose intravenous proton pump inhibitor)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Omeprazole (high-dose intravenous proton pump inhibitor) + Misoprostol (600 microg/day)
Number of subjects: 249
Study: 15057738

Group type: EXPERIMENTAL
Intervention: MRA (8 mg/kg biweekly)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MRA (every 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11442185

Group type: EXPERIMENTAL
Intervention: Topical verapamil (0.25%)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9758438

Group type: EXPERIMENTAL
Intervention: Iodine (0.5 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Levo-thyroxine (T4) (0.125 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Follow-up of patients who developed autoimmunity
Number of subjects: 62
Study: 7798975

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography
Number of subjects: 70

Group type: COMPARATOR
Intervention: Digital Subtraction Angiography
Number of subjects: 70
Study: 3044833

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus Poly(A).Poly(U)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 300
Study: 31161436

Group type: EXPERIMENTAL
Intervention: Netupitant and palonosetron (NEPA)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Aprepitant plus granisetron (APR + GRAN)
Number of subjects: 828
Study: 29256091

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 148
Study: 27878630

Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels measured at admission (122.44 ± 41.01 ng/ml)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels measured after treatment (71.38 ± 49.68 ng/ml)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels at admission (cutoff point of 45 ng/ml)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels at admission (cutoff point of 152 ng/ml)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment
Number of subjects: 50
Study: 26142168

Group type: EXPERIMENTAL
Intervention: Combined physical and occupational therapy (Group B, n=30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Physical therapy only (Group A, n=31)
Number of subjects: 61
Study: 23139265

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21992747

Group type: EXPERIMENTAL
Intervention: Induced ketosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17874244

Group type: EXPERIMENTAL
Intervention: Computer Assisted Surgery (CAS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard single incision technique (without CAS)
Number of subjects: 73
Study: 16644438

Group type: EXPERIMENTAL
Intervention: RT3D contrast echocardiography
Number of subjects: 14

Group type: COMPARATOR
Intervention: Noncontrast 3D imaging
Number of subjects: 14
Study: 12551742

Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study: 11015511

Group type: EXPERIMENTAL
Intervention: Early enteral iron supplementation (EI) of 2 to 6 mg/kg/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: Late enteral iron supplementation (LI)
Number of subjects: 133
Study: 8779128

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1500 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 2000 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Budesonide 2000 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 12
Study: 1355153

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: HLA typed with a donor
Number of subjects: 198
Study: 6354151

Group type: EXPERIMENTAL
Intervention: Corticotropin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) high‐dosage cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 0
Study: 30345574

Group type: EXPERIMENTAL
Intervention: SBIP + IMP
Number of subjects: 93

Group type: COMPARATOR
Intervention: SBIP
Number of subjects: 93
Study: 28718073

Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes (Oxabact™ OC3)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 26932324

Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cessation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education and stage of change post intervention
Number of subjects: 0
Study: 24152824

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22575719

Group type: EXPERIMENTAL
Intervention: Intervention focused on improving quality-of-life outcomes for co-occurring cancer and depression
Number of subjects: 24
Study: 20457366

Group type: EXPERIMENTAL
Intervention: Aspheric intraocular lens (IOL) implantation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Preoperative corneal spherical aberration
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Surgically induced corneal spherical aberration
Number of subjects: 37
Study: 17493072

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 40
Study: 15461066

Group type: EXPERIMENTAL
Intervention: Stage IIa PAD treatment
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Stage IIb PAD treatment
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Stage III PAD treatment
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Stage IV PAD treatment
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Overall treatment costs
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 280
Study: 11427189

Group type: EXPERIMENTAL
Intervention: Pre-operative assessment by appropriately trained nurses (ATN)
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Pre-operative assessment by pre-registration house officers (PRHO)
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Cost of pre-operative assessment by ATNs
Number of subjects: 1874
Study: 9530765

Group type: EXPERIMENTAL
Intervention: Psychoeducational training (10 sessions, attended at least 70%)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no psychoeducational training)
Number of subjects: 131
Study: 7979855

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 62

Group type: COMPARATOR
Intervention: No Tamoxifen (Placebo)
Number of subjects: 62
Study: 2606594

Group type: EXPERIMENTAL
Intervention: MaxEPA fish oil diet (6 g daily for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard diet rich in saturated lipids (control group)
Number of subjects: 14
Study: 782136

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 200 mug
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 400 mug
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 800 mug
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 27176943

Group type: EXPERIMENTAL
Intervention: Physical activity on Prescription (PaP) with conventional treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 88
Study: 25782227

Group type: EXPERIMENTAL
Intervention: GreenLight HPS 180-W laser (GLL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 62
Study: 23212498

Group type: EXPERIMENTAL
Intervention: Protected sleep period (12:30 AM to 5:30 AM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard intern schedule (no protected sleep)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Protected sleep period
Number of subjects: 103
Study: 20644583

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT) with effluent flow rates >25 ml/kg per hour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 0
Study: 18540016

Group type: EXPERIMENTAL
Intervention: Micro-implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 30
Study: 16411387

Group type: EXPERIMENTAL
Intervention: Otamixaban (escalating intravenous doses, 6-hour infusions: 1.7 to 183 microg/kg/h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Otamixaban (bolus dose: 30 or 120 microg/kg with 6-hour infusion: 60 or 140 microg/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12559941

Group type: COMPARATOR
Intervention: Thrombolysis (TL)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 850
Study: 11303326

Group type: EXPERIMENTAL
Intervention: CMA/B hCC chymase gene polymorphism assessment
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: CMA/B hCC chymase gene polymorphism assessment in female group without retinopathy
Number of subjects: 587
Study: 8839525

Group type: EXPERIMENTAL
Intervention: Inhaled beta-agonists
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Asthmatic subjects
Number of subjects: 48
Study: 1538048

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 131
Study: 6432291

Group type: EXPERIMENTAL
Intervention: Prednisone plus triple treatment (sodium fluoride, calcium, and vitamin D)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Only prednisone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (Prednisone plus triple treatment and Only prednisone)
Number of subjects: 31
Study: 31693997

Group type: EXPERIMENTAL
Intervention: 3 sets of 3 × 30‐second maximal sprints (E&S) during the first 3 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Work‐matched cycling without sprints (E)
Number of subjects: 12
Study: 29178404

Group type: EXPERIMENTAL
Intervention: Clinically diagnosed rickets at baseline
Number of subjects: 1778
Study: 27064797

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1262
Study: 24890170

Group type: EXPERIMENTAL
Intervention: Nano polymer‐free sirolimus‐eluting stent (SES)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Partner durable‐polymer sirolimus‐eluting stent (SES)
Number of subjects: 291
Study: 22369557

Group type: EXPERIMENTAL
Intervention: Long-term low dose aspirin therapy (75 mg and 150 mg)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (not taking aspirin)
Number of subjects: 308
Study: 19797410

Group type: EXPERIMENTAL
Intervention: Semi-Rapid Maxillary Expansion (SRME)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 35
Study: 17274715

Group type: EXPERIMENTAL
Intervention: Electronic device
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Magnetic device
Number of subjects: 17

Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 17
Study: 16129528

Group type: EXPERIMENTAL
Intervention: 5.5-week balance training programme (n=11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5.5-week balance training programme (n=8, volleyball group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n=11, no training)
Number of subjects: 30
Study: 11966498

Group type: EXPERIMENTAL
Intervention: Ranitidine, 75 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 10445639

Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 175

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 175
Study: 7789484

Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg q.d. oral therapy for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clarithromycin, 250 mg b.i.d. oral therapy for 10 +/- 2 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin and Clarithromycin
Number of subjects: 40